pargyline has been researched along with Nervous System Diseases in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benmansour, S; Brunswick, DJ | 1 |
| Behmand, RA; Harik, SI; Riachi, NJ | 1 |
| DeQuattro, V; Miura, Y | 1 |
3 other study(ies) available for pargyline and Nervous System Diseases
| Article | Year |
|---|---|
The MAO-B inhibitor deprenyl, but not the MAO-A inhibitor clorgyline, potentiates the neurotoxicity of p-chloroamphetamine.
Topics: Animals; Autoradiography; Body Temperature; Brain; Clorgyline; Drug Synergism; Iodocyanopindolol; Male; Nerve Endings; Nervous System Diseases; Neurons; p-Chloroamphetamine; Pargyline; Pindolol; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; Selegiline; Serotonin | 1994 |
Correlation of MPTP neurotoxicity in vivo with oxidation of MPTP by the brain and blood-brain barrier in vitro in five rat strains.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Biogenic Amines; Blood-Brain Barrier; Brain Chemistry; Carotid Arteries; Cerebral Cortex; Corpus Striatum; Dopamine; Injections, Intra-Arterial; Male; Microcirculation; Monoamine Oxidase; MPTP Poisoning; Nervous System Diseases; Oxidation-Reduction; Pargyline; Rats; Rats, Inbred F344; Rats, Inbred Strains; Species Specificity | 1991 |
Neurogenic factors in human hypertension: mechanism or myth?
Topics: Angiotensin II; Blood Pressure; Catecholamines; Chemical Phenomena; Chemistry; Dihydroxyphenylalanine; Epinephrine; Humans; Hypertension; Hypertension, Renal; Male; Nervous System Diseases; Norepinephrine; Pargyline; Physical Exertion; Posture; Reserpine; Sympathetic Nervous System; Tritium | 1973 |